Autolus Therapeutics plc, ticker symbol AUTL, is a clinical-stage biopharmaceutical venture that is devoted to developing transformative therapies for challenging oncology cases. Established in 2014, this UK-based company focuses on providing next-generation programmed T cell therapies to patients. Autolus Therapeutics primarily designs product candidates to overcome cancer defense mechanisms and use the body's natural immune system to fight the disease.
The company's diverse portfolio comprises several projects targeting critical pathways in hematological malignancies, solid tumors, and other malignant diseases. Their key products under investigation include AUTO1, AUTO3, AUTO4 and AUTO6, all of which aim to improve outcomes for cancer patients in dire need of safer, effective treatments. Notably, AUTO1, developed for adult acute lymphoblastic leukemia (ALL), has received Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).
A critical part of Autolus' operating platform is its capacity for innovation in science and manufacturing, which is essential for achieving their strategic objectives. Their innovative approach to programming T cells is aimed at increasing the effectiveness and safety of these therapies while also establishing predictable and consistent manufacturing of their specialized treatments.
Under the leadership of a seasoned management team with extensive experience in cellular therapy and the pharmaceutical industry, Autolus Therapeutics continues its pursuit of groundbreaking results. It remains committed to its mission of bringing innovative cancer treatments to patients through its pioneered science and advanced cellular therapeutic technology, while creating value for stakeholders and the broader medical community.
The company's proactive business model, combined with a dedicated focus on research and the potential to address unmet medical needs, promise significant business potential. Shares of Autolus Therapeutics plc are traded on the NASDAQ Global Select Market, and its performance is closely watched by investors interested in biopharmaceutical stocks with substantial growth prospects.
During the course of its operation, Autolus has forged collaborations with some of the world's leading medical and research institutions, aligning the strengths of the academic and pharmaceutical industries. As a part of this network, Autolus confirms its belonging to the vibrant community engaged in ushering in the next phase of cancer treatment. Nonetheless, it's important to note that the company's journey represents a risky bet on developing a viable commercial product, like many in the biotech industry. Yet, the potential rewards could be significant if they can take transformative immunotherapies from the lab to the market efficiently.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Autolus Therapeutics plc (NASDAQ: AUTL), a London-based clinical-stage biopharmaceutical company, is highlighted for its significant 354.43% potential upside according to recent analyst ratings. With a market cap of $511.03 million, the company is developing innovative T cell therapies for cancer and autoimmune diseases, including AUCATZYL and obe-cel. Despite current unprofitability and high R&D costs typical of biotech startups, strong analyst support and an ambitious average price target of $8.73 suggest promising growth potential for investors willing to embrace the associated risks.
Autolus Therapeutics (AUTL) reported significant second-quarter revenue growth, with net product revenue hitting $45.7 million, a 119% increase year-over-year, driven by its CAR T therapy AUCATZYL. Despite this sales explosion and an improved gross margin, the company remains unprofitable, posting a net loss of $39.1 million for the quarter. While new financing has extended its cash runway, profitability and consistent cash generation remain key challenges for investors.
Autolus Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for obe-cel, intended for systemic lupus erythematosus (SLE) and lupus nephritis (LN) treatment. This designation aims to accelerate the development and review of obe-cel, addressing a significant unmet need for patients with severe refractory autoimmune diseases. The company is advancing obe-cel through its pivotal Phase 2 LUMINA study and expects to report data in 2028.
Piccina Cintia, U.S. Chief Commercial Officer and Country General Manager at Autolus Therapeutics plc, recently exercised options to acquire 20,000 shares and subsequently sold 6,713 shares. These transactions, reported on September 1st and 2nd, 2026, resulted in her holding 13,287 shares and 60,000 derivative securities. The report provides updated ownership details for investors, highlighting the exercise of options at $2.35 per share and the sale at $2.34 per share.
Cintia Piccina, U.S. Chief Commercial Officer and Country General Manager at Autolus Therapeutics plc, filed a Form 4 detailing recent transactions. On September 1, 2026, 20,000 Restricted Share Units vested, and on September 2, 2026, she sold 6,713 American Depositary Shares. Following these transactions, Piccina directly owns 13,287 American Depositary Shares and retains beneficial ownership of 60,000 RSUs, which are scheduled to vest in four annual installments.
Autolus (AUTL) reported strong Q2 2026 results with net product revenue of $45.7 million, a 119% year-over-year increase, leading to an increased full-year guidance of $140 million to $150 million. The company achieved a gross margin of 55% and extended its cash runway into Q2 2028 through strategic financing and cost reductions. Autolus is expanding its market presence in the U.S. and U.K. while advancing its clinical pipeline for multiple sclerosis, pediatric ALL, and lupus nephritis.
Alphabet Inc. has acquired a new position in Autolus Therapeutics PLC Sponsored ADR (